Aqueous Humor Dynamics and Hypertensive Uveitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02765308|
Recruitment Status : Completed
First Posted : May 6, 2016
Last Update Posted : August 1, 2017
Uveitis is a disease that affects over 2 million people around the globe, and can ultimately lead to blindness. The proportion of patients with uveitis who become blind has not been reduced over the past 30 years, and this is therefore an area that demands further research. One of the major causes of blindness in uveitic patients is the development of uveitic glaucoma, which occurs in 10-20% of uveitic eyes. This is likely to occur for reasons related to the uveitis itself, but can also be caused as a side effect of the corticosteroids used to treat uveitis. The raised IOP in uveitis is more difficult to treat than other types of glaucoma.
To enable more effective treatment of uveitic glaucoma, the investigators need to understand more clearly the mechanisms which underlie this process. The investigators therefore propose a study to examine the contribution of altered aqueous dynamics to the development of raised IOP in uveitis.
|Condition or disease|
|Uveitic Glaucoma Anterior Uveitis|
|Study Type :||Observational|
|Actual Enrollment :||94 participants|
|Official Title:||The Contribution of Altered Aqueous Dynamics in the Development of Raised Intraocular Pressure in Patients With Uveitis|
|Study Start Date :||August 2013|
|Actual Primary Completion Date :||December 2016|
|Actual Study Completion Date :||December 2016|
healthy age matched with cases volunteers as controls
Uveitis with raised IOP
Recurrent (> 5 attacks) idiopathic acute anterior uveitic with raised intraocular pressure
Uveitis with with normal IOP
Recurrent (> 5 attacks) idiopathic acute anterior uveitic with normal intraocular pressure
- Facility of outflow [ Time Frame: day 1 only (study completion) ]Tonographic outflow facility (C) will be performed using an electronic Schiøtz tonographer (Model 720, Berkeley Bioengineering Inc, USA) at 10AM
- Rate of aqueous flow (measured by fluorophotometry). [ Time Frame: Four times during the morning through day 1 only (study completion) ]Fluorophotometry will be performed in both eyes using a scanning ocular fluorophotometer from 9AM to 12PM (FM-2, Fluorotron Master Ocular Fluorophotometer; OcuMetrics, Mountain View, California). The aqueous turnover protocol will be used to calculate the aqueous flow rate. Duplicate or triplicate scans will be collected and repeated at 1 hour intervals for 4 measurements to determine the aqueous flow rate (Ft).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02765308
|Guys and St Thomas NHS Foundation Trust|
|London, United Kingdom, SE1 7EH|
|Principal Investigator:||K Sheng l, MD||Guy's and St Thomas NHS Foundation Trust|